A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...
In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures ...
The Inflation Reduction Act (IRA) of 2022 introduced sweeping changes to the US prescription drug market, most notably ...
A conservative 3% trend means a $100 billion Medicare Advantage book could face a $3 billion shortfall. Even before the Final ...
In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while ...
In today’s Pharma Pulse, UK regulators seize thousands of fake weight loss pens, while new data reveals that the "miracle jab" is financially out of reach for nearly 70% of users.
In today’s Pharma Pulse, BioNTech escalates its patent battle against Moderna over next-gen COVID shots, while a new ...
In the first part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, explains how third ...
In today’s Pharma Pulse, Eli Lilly launches the monthly Zepbound KwikPen to streamline obesity care, while Gilead Sciences moves to acquires Arcellx in a massive expansion of its cell therapy ...
In today’s Pharma Pulse, Johnson & Johnson commits over $1 billion to a new biomanufacturing site in Pennsylvania, while Hims ...
The pharmaceutical industry now emphasizes gross-to-net revenue, driven by specialty drugs and rare-disease therapies, rather than market share. Pharmacy benefit managers (PBMs) significantly impact ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results